Creating better monoclonal antibody formulations using AI and automation
Data-Driven Antibody Formulation in a Self-Driving Lab
['FUNDING_R01'] · RUTGERS, THE STATE UNIV OF N.J. · NIH-11105060
This study is working on using smart technology to make better and faster versions of medicines called monoclonal antibodies, which help treat various conditions, by finding the best ingredients to keep them stable and effective, especially for easy injections under the skin.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS, THE STATE UNIV OF N.J. (nih funded) |
| Locations | 1 site (PISCATAWAY, UNITED STATES) |
| Trial ID | NIH-11105060 on ClinicalTrials.gov |
What this research studies
This research focuses on developing advanced methods to formulate monoclonal antibodies (mAbs) more efficiently using artificial intelligence and automation. By leveraging data science techniques, the project aims to identify optimal combinations of safe additives that enhance the stability and performance of mAbs, particularly for subcutaneous dosing. The approach includes prototyping experimental methodologies, conducting AI-driven formulation searches, and integrating these into a self-driving laboratory system. This innovative pipeline could significantly improve the formulation process, making it faster and more effective for future treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients requiring monoclonal antibody therapies, particularly those needing subcutaneous administration.
Not a fit: Patients who do not require monoclonal antibody treatments or those with conditions not addressed by these therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and stable monoclonal antibody treatments for patients.
How similar studies have performed: Other research has shown promise in using AI and automation for drug formulation, indicating a potential for success in this novel approach.
Where this research is happening
PISCATAWAY, UNITED STATES
- RUTGERS, THE STATE UNIV OF N.J. — PISCATAWAY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GORMLEY, ADAM JOSEPH — RUTGERS, THE STATE UNIV OF N.J.
- Study coordinator: GORMLEY, ADAM JOSEPH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.